https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33674  0.800) were comparable. At the cut-off points for mild depression of 53, the PROMIS measures had sensitivity (0.83 for PROMIS-D-CAT and 0.80 for PROMIS-D-SF) similar to or better than 6/7 legacy measures with high negative predictive value (> 90%). At cut-off points of 60 for moderate depression, PROMIS measures had specificity > 90%, similar to or better than all legacy measures and positive predictive value ≥ 0.50 (similar to 5/7 legacy measures). Conclusions: The convergent and criterion validity of the PROMIS depression measures in cancer populations was confirmed, although the optimal cut-off points are not established. PROMIS measures were briefer than BDI-II and CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other legacy measures of depression in oncology patients.]]> Wed 23 Feb 2022 16:02:07 AEDT ]]> A Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) among cancer survivors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13571 Wed 11 Apr 2018 11:52:42 AEST ]]> Convergent and criterion validity of PROMIS anxiety measures relative to six legacy measures and a structured diagnostic interview for anxiety in cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51823 .80) were good for both PROMIS measures and comparable to or better than all legacy measures. At the recommended mild cut-point (55), PROMIS-A-SF had sensitivity (.67) comparable to or better than all the legacy measures, whereas PROMIS-A-CAT sensitivity (.59) was lower than GAD-7 (.67) and HADS-A (.62), but comparable to PSYCH-6 and higher than DASS-A, DASS-S and DT. Sensitivity for both was.79. A reduced cut-point of 51 on both PROMIS measures improved sensitivity (.83–.84) although specificity was only adequate (.61–.62). Conclusions: The convergent and criterion validity of the PROMIS anxiety measures in cancer populations was confirmed as equivalent, but not superior to, established measures (GAD-7 and HADS-A). The PROMIS-A-CAT did not demonstrate clear advantages over PROMIS-A-SF.]]> Wed 08 May 2024 09:59:12 AEST ]]> Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus–Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55237 Wed 01 May 2024 15:42:40 AEST ]]> Phase 3 trial of domiciliary humidification to mitigate acute mucosal toxicity during radiation therapy for head-and-neck cancer: first report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20970 Sat 24 Mar 2018 07:54:21 AEDT ]]> Using Rasch analysis to examine the distress thermometer's cut-off scores among a mixed group of patients with cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18587 Sat 24 Mar 2018 07:50:16 AEDT ]]> Making sense of variations in prevalence estimates of depression in cancer: a co-calibration of commonly used depression scales using rasch analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24153 Sat 24 Mar 2018 07:09:44 AEDT ]]> Apples to apples? Comparison of the measurement properties of hospital anxiety and depression-anxiety subscale (HADS-A)... https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44472 Fri 14 Oct 2022 08:43:40 AEDT ]]>